Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tumour necrosis factor alpha kinoid

Next Previous
Drug Profile

Tumour necrosis factor alpha kinoid

Alternative Names: TNF-K; TNF-K005; TNFα-kinoid

Latest Information Update: 07 Sep 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neovacs
  • Class Antirheumatics; Antiulcers; Vaccines
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Crohn's disease; Rheumatoid arthritis

Most Recent Events

  • 07 Sep 2021 Discontinued - Phase-I/II for Crohn's disease in South Africa, Switzerland (IM) (Neovacs pipeline, September 2021)
  • 07 Sep 2021 Discontinued - Phase-II for Crohn's disease in France, Belgium, Germany, Netherlands, Bulgaria, Czech Republic, Hungary, Croatia, Romania (IM) (Neovacs pipeline, September 2021)
  • 07 Sep 2021 Discontinued - Phase-II for Rheumatoid arthritis in Argentina, Belgium, Bulgaria, Chile, Croatia, Czech Republic, France, Georgia, Hungary, Lebanon, Macedonia, Moldova, Poland, Romania, Russia, Serbia, Ukraine (IM) (Neovacs pipeline, September 2021)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top